Telomir Pharmaceuticals (TELO) to Release Earnings on Tuesday

Key Points

• Telomir Pharmaceuticals is set to announce its earnings on Tuesday, August 12th, with analysts predicting a quarterly loss of ($0.08) per share.
• As of recently, TELO shares are down 0.8% to $1.82, with a market cap of $54.01 million and a P/E ratio of -4.32.
• A hedge fund, Bank of America Corp DE, increased its stake in Telomir Pharmaceuticals by 283.9% in the last quarter, acquiring an additional 10,880 shares.

Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) is expected to be announcing its earnings results before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.03. On average, analysts expect Telomir Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Telomir Pharmaceuticals Trading Down 6.6%

Shares of Telomir Pharmaceuticals stock traded down $0.11 during trading hours on Friday, reaching $1.56. 513,610 shares of the company's stock were exchanged, compared to its average volume of 9,265,380. Telomir Pharmaceuticals has a 52-week low of $1.12 and a 52-week high of $8.40. The company has a fifty day moving average of $1.72 and a 200-day moving average of $2.86. The firm has a market capitalization of $46.43 million, a price-to-earnings ratio of -3.71 and a beta of -0.67.

Institutional Investors Weigh In On Telomir Pharmaceuticals

An institutional investor recently raised its position in Telomir Pharmaceuticals stock. Bank of America Corp DE increased its position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO - Free Report) by 283.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,713 shares of the company's stock after purchasing an additional 10,880 shares during the quarter. Bank of America Corp DE's holdings in Telomir Pharmaceuticals were worth $61,000 as of its most recent filing with the Securities and Exchange Commission.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.